Kevin Chen China

Wuxi Xinwu District
Partnering Objectives
Headquartner in China
Wuxi international life science innovation campus
Investment promotion manager 

ming chen China

haitong
Website:
www.haitong.com
Partnering Objectives
Headquartner in China
haitong security
analyst 

Denise Chen China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Medtech Development Stage
GIG
Partner 
Functionality

Paul Chen China

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Looking to in-license / out-license
Headquartner in China
Biotech/Pharma Asset Stage
Reistone Biopharma
Chief of Staff 
Functionality

Mr Jim Chen China

Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion.  It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas.   Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.

For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.

Website:
www.chasesun.cn
Company Size (Fulltime employees)
Year of foundation
1996
Headquartner in China
Biotech/Pharma Asset Stage
Tianjin chasesun pharmaceutical co ltd
Investment Manager 
Functionality

Mr. Mark Chen China

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Company Size (Fulltime employees)
Year of foundation
2009
Partnering Objectives
Please specify your partnering goal
Licensing-in
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Kintor Pharmaceuticals
BD Director 
Functionality

Guofeng Cheng China

Biotech
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
AusperBio
CEO 

Mr. Cliff Cheng China

A pharmaceutical company
Website:
www.buchang.com
Company Size (Fulltime employees)
Please specify your partnering goal
licensing-in and partnership
Headquartner in China
Buchang Pharma Group
CSO 

Haipeng Cheng China

Sangel Capital provides venture capital and business finance to support high-tech enterprises in China and US. The firm seeks to invest in innovative startups in sectors including biopharma, diagnostics, medical devices, and biotech.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.
Sangel Capital

Mr. Chris Chow China

Hong Kong Biotechnology Organization is an independent nonprofit organization with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.
Company Size (Fulltime employees)
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
International Convention in Hong Kong
Headquartner in China
Your Research Tool and Service name
BIOHK2021
Service Description
Hong Kong Biotechnology Organization is going to hold an International Biotechnology Convention in Hong Kong in 2021. BIOHK2021 guarantees the perfect opportunity to best tap into this vast market, completing our biotech ecosystem as Asia emerges as the world’s next biotech powerhouse. BIOHK2021 is fully supported by HKSAR Government, where the Innovation and Technology Commission and Commerce has provided funding for our conference and the Commerce and Economic Development Bureau has made BIOHK2021 a key project in Hong Kong’s “relaunch program”. Furthermore, the event is also supported by the Torch Project from The Ministry of Science and Technology PRC. (Quoted: President Xi Jinping said ‘the Central Government will promote collaboration between Hong Kong and the Mainland on the technology front and support Hong Kong to become an international innovation and technology hub.’). These commitments to BIOHK2021 prove how essential and important the convention will be.
Target client type
All biotech stakeholders
Hong Kong Biotechnology Organization
Sales Manager 
Functionality